Marilyne Failly
pDNA Development & Industrialization Sanofi
Seminars
Thursday 26th March 2026
Leveraging Advanced QbD Analytics to Define CQAs & Optimize Plasmid DNA for mRNA Therapeutics
11:30 am
- Define and control critical quality attributes for mRNA, ensuring consistency, potency, and purity throughout development and scale-up
- Strengthen in-process controls and release testing frameworks to better link analytical outcomes with product performance and regulatory expectations
- Leverage advanced analytical tools for in-depth characterization
